Create your page here
Latest News for: rituxan
Edit
Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indication of Systemic Sclerosis (Chugai Pharmaceutical Co Ltd)
Public Technologies 27 Sep 2021
Edit
Global Top Selling Biologics Markets 2021-2030: Humira, Keytruda, Opdivo, Avastin, Rituxan, Stelara, Herceptin, Enbrel
PR Newswire 03 Aug 2021
DUBLIN, Aug ... In the recent past, many biological interventions have achieved blockbuster status (in some cases, registering revenues worth over USD 4 billion in a year); prominent examples include (as per decreasing revenues generated in 2020) Humira, Keytruda, Stelara, Opdivo, Avastin, Trulicity, Enbrel, OcrevusT and Rituxan ... Key Topics Covered.. 1 ... .
Edit
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan ...
Business Wire 04 May 2021
IBRX), a clinical-stage immunotherapy company, today announced the launch of the preclinical ...
Edit
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients (Immunitybio Inc)
Public Technologies 04 May 2021
Edit
Vaccines Won’t Protect Millions of Patients With Crippled Immune Systems
New York Times 15 Apr 2021
Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help. monoclonal antibodies ... .
Edit
Vaccines Won’t Protect Millions of Patients With Weakened Immune Systems
New York Times 15 Apr 2021
Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help. monoclonal antibodies ... .
Edit
FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
PR Newswire 17 Dec 2020
Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA).
Edit
FDA Approves Amgen's RIABNI(TM) (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
Pharmiweb 17 Dec 2020
Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA).
Edit
FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab) (Amgen Inc)
Public Technologies 17 Dec 2020
Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA).
Edit
New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
Public Technologies 07 Dec 2020
GO29365 [NCT02257567] is a global, phase Ib/II study evaluating the safety, tolerability and activity of Polivy® (polatuzumab vedotin) in combination with bendamustine and MabThera®/Rituxan® (rituximab) (BR) or Gazyva®/Gazyvaro® (obinutuzumab) in relapsed or refractory (R/R) follicular lymphoma or diffuse large B-cell lymphoma (DLBCL).
- 1
